Suppr超能文献

肾脏疾病与高血压中的肠道微生物群。

Gut microbiota in kidney disease and hypertension.

机构信息

Hypertension Center, 3rd Department of Internal Medicine, Papageorgiou Hospital, Aristotle University, Thessaloniki, Greece.

1st Department of Pediatrics, Aristotle University, Thessaloniki, Greece.

出版信息

Pharmacol Res. 2018 Apr;130:198-203. doi: 10.1016/j.phrs.2018.02.028. Epub 2018 Feb 26.

Abstract

The human gut microbiota is being composed of more than one hundred trillion microbial cells, including aerobic and anaerobic species as well as gram-positive and negative species. Animal based evidence suggests that the change of normal gut microbiota is responsible for several clinical implications including blood pressure increase and kidney function reduction. Trimethylamine-N-Oxide, short-chain fatty acids and inflammatory factors are originated from the gut microbes and may induce changes in arteries, kidneys and blood pressure. Prebiotics and probiotics change the gut microbiota and may reduce high blood pressure and ameliorate chronic kidney disease suggesting a new treatment target in patients for the initial stages of hypertension concomitant with other life style changes such as increased physical exercise and weight reduction to reduce cardiovascular disease complications.

摘要

人类肠道微生物群由超过一万亿个微生物细胞组成,包括需氧和厌氧物种以及革兰氏阳性和阴性物种。动物研究证据表明,正常肠道微生物群的变化与包括血压升高和肾功能下降在内的几种临床意义有关。三甲胺 N-氧化物、短链脂肪酸和炎症因子来源于肠道微生物,可能导致动脉、肾脏和血压的变化。益生元和益生菌改变肠道微生物群,可能降低高血压并改善慢性肾脏病,这表明在高血压的初始阶段,除了增加身体活动和减轻体重等其他生活方式改变以减少心血管疾病并发症外,患者可能有新的治疗靶点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验